
Camena has developed a wholly novel and proprietary enzymatic technology to accurately produce synthetic DNA. Unlike other enzymatic approaches, Camena does not use TdT, therefore overcoming the limitations inherent in this methodology.
- Investment status Current
- Invested 2023
- Category Health & Life Sciences